Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults

• Status: Completed
• Trial end date: 2010-06-01

Summary

The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.

• Phase: Phase 4

Details

• Lead Sponsor: Nicola Goekbuget
• Treatments: Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Ifosfamide; Methotrexate; Prednisolone; Rituximab; Vincristine; Vindesine